Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Safinamide for Levodopa-induced Dyskinesia (PD-LID)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03987750
Recruitment Status : Not yet recruiting
First Posted : June 17, 2019
Last Update Posted : June 17, 2019
Sponsor:
Information provided by (Responsible Party):
Zambon SpA

Brief Summary:
This will be a prospective, multi-center, randomized, double-blind, parallel group, placebo-controlled study, in participants with PD who are on a stable regimen of dopaminergic medication and have at least mild levodopa-induced dyskinesia. Eligible participants will be randomized to one of three treatment groups to receive adjunctive daily treatment with either safinamide 100 mg, safinamide 150 mg or placebo in a 1:1:1 ratio. Outcome will be assessed after 26 weeks of treatment.

Condition or disease Intervention/treatment Phase
Dyskinesia, Drug-Induced Parkinson Disease Drug: Safinamide Methanesulfonate 150mg Drug: Safinamide Methanesulfonate 100mg Drug: Safinamide Methanesulfonate matching placebo Phase 3

Detailed Description:

Trial participation will be up to a maximum duration of 32 weeks and will comprise:

  • Screening period (up to 4 weeks) for screening assessments;
  • Two weeks titration period: participants randomized to the 100 mg study arm will receive 100 mg during Week 1 and throughout the rest of the study; participants randomized to the 150 mg study arm will receive 100 mg during Weeks 1 and 2 , and 150 mg from Week 3 and throughout the rest of the study; participants randomized to the placebo arm will receive identical placebo tablets.
  • Twenty-four weeks maintenance period during which patients receive their randomized treatment as an adjunct to their standard anti-PD medications, which should remain unaltered. End of treatment evaluations will be performed at the end of Week 26 or at early discontinuation
  • A telephone follow-up call will be performed 2 weeks after the end of treatment to assess adverse events and concomitant medications

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 300 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 3, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy and Safety of 2 Doses of Safinamide Compared to Placebo in the Treatment of LID in PD Patients With Motor Fluctuations
Estimated Study Start Date : October 2019
Estimated Primary Completion Date : April 2021
Estimated Study Completion Date : May 2021

Resource links provided by the National Library of Medicine

Drug Information available for: Safinamide

Arm Intervention/treatment
Experimental: Safinamide 100mg
Participants randomized to the 100 mg study arm will receive 100 mg safinamide methanesulfonate film-coated tablets once daily during Week 1 (2 x 50 mg active tablets plus 1 placebo tablet) and throughout the rest of the study safinamide
Drug: Safinamide Methanesulfonate 100mg
100 mg (free base)

Experimental: Safinamide 150mg
Participants randomized to the 150 mg study arm will receive 100 mg methanesulfonate film-coated tablets once daily during Weeks 1 and 2 (2 x 50 mg active tablets plus 1 placebo tablet), and 150 mg methanesulfonate film-coated tablets once daily(3 x 50 mg active tablets) from Week 3 and throughout the rest of the study
Drug: Safinamide Methanesulfonate 150mg
150 mg (free base)

Placebo Comparator: Placebo
Participants randomized to the placebo arm will receive Safinamide Methanesulfonate matching placebo film-coated tablets once daily (3 x placebo tablets)
Drug: Safinamide Methanesulfonate matching placebo
placebo




Primary Outcome Measures :
  1. Assess the effect of two doses of safinamide on reducing levodopa-induced dyskinesia [ Time Frame: 26 weeks ]
    Change from Baseline to Week 26 in levodopa-induced dyskinesia based on UDysRS total score. The UDysRS is a dyskinesia rating scale from 0-104; it evaluates involuntary movements associated with PD. A higher score indicates more severe PD


Secondary Outcome Measures :
  1. Assess the effect of two doses of safinamide on ON time with No Dyskinesia [ Time Frame: 26 weeks ]
    Change from Baseline (Day 1 prior to start of study intervention) to Week 26 total daily ON time with No dyskinesia based on PD Home Diary. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.

  2. Assess the effect of two doses of safinamide on ON time with non-troublesome dyskinesia [ Time Frame: 26 weeks ]
    Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily ON time with non-troublesome dyskinesia. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.

  3. Assess the effect of two doses of safinamide on ON time with troublesome dyskinesia [ Time Frame: 26 weeks ]
    Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily ON time with troublesome dyskinesia. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.

  4. To assess the effect of two doses of safinamide on ON time with any dyskinesia (troublesome or non-troublesome) [ Time Frame: 26 weeks ]
    Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily ON time with any dyskinesia (troublesome or non-troublesome). A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.

  5. To assess the effect of two doses of safinamide on sleep time [ Time Frame: 26 weeks ]
    Change from Baseline (48 hours prior to Day 1) to Week 26 based on PD Home Diary in total daily sleep time. A PD home diary is used to score 5 different conditions : ASLEEP, OFF, ON (ie, had adequate control of PD symptoms) without dyskinesia, ON with non-troublesome dyskinesia, and ON with troublesome dyskinesia.

  6. To assess the effect of two doses of safinamide on Movement Disorder Society-Sponsored Unified Parkinson's Disease Rating Scale (MDS-UPDRS) total score and sub-scores [ Time Frame: 26 weeks ]
    Change from Baseline (Day 1 prior to start of study intervention) to Week 26 in MDS-UPDRS total score and sub-scores. The MDS-UPDRS is divided into 4 parts. In each part, all items are rated on a scale from 0 (normal) to 4 (severe impairment); Part I assesses 15 items of non-motor aspects of experiences of daily living; Part II comprises 13 items evaluating the impact of PD on patients' activities of daily living (ADL) over the week prior to the visit such as speech, salivation, swallowing, eating, handwriting, dressing, turning in bed, walking; part III assesses the motor abilities in PD patients at the time of the visit; Part IV assesses motor complications of therapy, such as dyskinesias, motor fluctuations.

  7. To assess the effect of two doses of safinamide on Clinician Global Impression of Change (CGIc) [ Time Frame: 26 weeks ]
    Clinician Global Impression of Change (CGIc) at Week 26. CGI-C is a 7-point scale used by Investigator to rate patient's overall improvement using a range of responses from 1 (very much improved) through to 7 (very much worse).

  8. To assess the effect of two doses of safinamide on Patient Global Impression of Change (PGIc) [ Time Frame: 26 weeks ]
    Patient Global Impression of Change (CGIc) at Week 26. PGI-C is a 7-point scale depicting a patient's rating of overall improvement using a range of responses from 1 (very much improved) to 7 (very much worse).

  9. To assess the effect of two doses of safinamide on PDQ-39 summary index [ Time Frame: 26 weeks ]
    Change from Baseline (Day 1 prior to start of study intervention) to Week 26 in PDQ-39 summary index. The PDQ-39 is a specific tool to assess quality of life in PD. Comprises 39 items divided into eight dimensions: mobility, activities of daily living (ADLs), emotional well-being, stigma, social support, cognition, communication and physical discomfort, where scores range from 0-100, with the higher, the worse the perception of quality of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   30 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Male and female participants aged 30 years and above at the time of signing the informed consent;
  2. Female participants may participate if they are not of child bearing potential (post-menopausal with no periods for at least one year, or surgically sterilized);
  3. Women of child bearing potential (WOCBP) may participate if they are not pregnant, not breastfeeding, and agree to follow the contraceptive guidance during the treatment period and for at least 30 days after the last dose of study intervention;
  4. A diagnosis of Parkinson's disease consistent with the UK PD Brain Bank Society and MDS Clinical Diagnostic Criteria;
  5. Levodopa immediate release and/or controlled release, given at least 3 times daily, on a stable regimen for at least 4 weeks prior to screening;
  6. Participants may also be taking benserazide, catcechol O methyl transferease (COMT) inhibitors and dopamine agonists, the dose of which must be stable for at least 4 weeks prior to screening;
  7. Predictable peak dose dyskinesia of at least mild severity and causing at least mild disability as defined as a score of ≥2 on the MDS UPDRS questions 4.1 and 4.2 at screening and at least two 30 minute periods of ON time with troublesome dyskinesia recorded in 24 hour PD home diaries performed in each of the two days prior to the randomization visit;
  8. Participants with motor fluctuations with at least three 30 minute periods in OFF (for a total of 1.5 hours per waking day) in each of the two consecutive 24 hour home diaries completed at the end of the screening period in the 48 hours prior to Day 1
  9. Provided written informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, prior to the study screening procedures commencing.

Exclusion Criteria:

  1. Participants with secondary or atypical parkinsonian syndrome
  2. Participants with solely diphasic dyskinesia without peak dose dyskinesia
  3. History of neurosurgical procedure for Parkinson's disease, including stereotactic surgery and Deep Brain Stimulation (DBS).
  4. Treatment with monoamine oxidase inhibitors, amantadine pethidine, dextromethorphan, fluoxetine, fluvoxamine in the 8 weeks prior to the screening visit
  5. Concomitant use of selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic/tetracyclic antidepressants may be permitted but used at the lowest doses.
  6. Participants who are unable to complete the home diary and have 2 consecutive 24-hour periods with more than 4 missing periods per 24 hours in the diary, completed at the end of the screening period, in the 48 hours prior to Day 1
  7. History of major psychiatric disease eg bipolar disorder, severe depression, schizophrenia or other psychosis.
  8. Current history of Impulse Control Disorder
  9. History of drug and/or alcohol abuse within 12 months prior to screening (DSM-V criteria)
  10. History of dementia (DSM-V criteria) or cognitive impairment MMSE < 24 at screening
  11. Ophthalmologic history of the following conditions: albinism, uveitis, retinitis pigmentosa, retinal degeneration, active retinopathy, severe progressive diabetic retinopathy, inherited retinopathy or family history of hereditary retinal disease.
  12. Moderate or severe hepatic impairment with transaminases >2 times upper limit of normal (ULN) or bilirubin 1.5 times ULN
  13. Any clinically significant or unstable medical or surgical condition that, in the opinion of the investigator, might preclude safe completion of the study or might affect the results of the study.
  14. Use of any investigational drug within 30 days prior to screening or 5 half-lives, whichever is the longest.
  15. Allergy/sensitivity or contraindications to the investigational medicinal product (IMP) or their excipients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03987750


Contacts
Layout table for location contacts
Contact: Elena Tiberio +39 02 6652 ext 4602 elena.tiberio@zambongroup.com

Sponsors and Collaborators
Zambon SpA
Investigators
Layout table for investigator information
Study Director: Charlotte Keywood, MD Zambon SpA

Layout table for additonal information
Responsible Party: Zambon SpA
ClinicalTrials.gov Identifier: NCT03987750     History of Changes
Other Study ID Numbers: Z7219L04
First Posted: June 17, 2019    Key Record Dates
Last Update Posted: June 17, 2019
Last Verified: June 2019

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Dyskinesias
Dyskinesia, Drug-Induced
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Neurologic Manifestations
Signs and Symptoms
Neurotoxicity Syndromes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Poisoning